In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 51 to 75 of 404

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]	Technology appraisal guidance	TBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]	Technology appraisal guidance	TBC
Bipolar disorder: assessment and management (extraordinary review)	NICE guideline	TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]	Technology appraisal guidance	26 March 2025
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]	Technology appraisal guidance	TBC
Breast cancer guidelines	NICE guideline	TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]	Technology appraisal guidance	28 January 2025
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325](review of TA677)	Technology appraisal guidance	10 September 2025
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]	Technology appraisal guidance	TBC
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]	Technology appraisal guidance	29 January 2025
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]	Technology appraisal guidance	24 May 2019
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474	Technology appraisal guidance	TBC
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330]	Technology appraisal guidance	TBC
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]	Technology appraisal guidance	TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]	Technology appraisal guidance	5 March 2025
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]	Technology appraisal guidance	TBC
Cardiometabolic disease prevention and treatment guidelines	NICE guideline	TBC
Cardiovascular risk assessment and lipid modification	Quality standard	23 July 2025
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]	Technology appraisal guidance	TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]	Technology appraisal guidance	30 April 2025
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]	Highly specialised technology	TBC
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure	NICE guideline	TBC
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]	Technology appraisal guidance	TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]	Technology appraisal guidance	TBC
Cladribine for treating relapsing multiple sclerosis [ID6263]	Technology appraisal guidance	5 February 2025

Results per page

10
25
50
All